NCT05775159 2026-04-17
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
Phase 2 Recruiting
Clinical Trials
24 trialsNCT06467357 2026-04-16
DESTINY-BTC01
AstraZeneca
Phase 3 Recruiting
NCT05771480 2026-03-25
TOURMALINE
AstraZeneca
Phase 3 Active not recruiting
NCT06282575 2026-03-24
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT05489211 2026-03-19
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT07221253 2026-03-17
AB02
AstraZeneca
Phase 3 Recruiting
NCT06109779 2026-03-04
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
AstraZeneca
Phase 3 Active not recruiting
NCT07398339 2026-02-09
DVDMS
Shanghai Guangsheng Biopharmaceutical Co., Ltd
Phase 2 Recruiting
NCT06428409 2026-01-22
MK-9999-02A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06591520 2026-01-21
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Akeso
Phase 3 Active not recruiting
NCT04956640 2025-09-25
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Phase 1/2 Recruiting
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT03314935 2025-08-12
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT02711553 2025-08-03
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company
Phase 2 Active not recruiting
NCT06465563 2025-01-27
Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT06611345 2024-10-26
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase NA Recruiting
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04677504 2024-07-03
A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT04066491 2023-11-14
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
EMD Serono
Phase 2/3 Terminated
NCT05116891 2023-07-03
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
Phase 1/2 Completed
NCT03790111 2023-04-19
TELE-ABC
TerSera Therapeutics LLC
Phase 2 Terminated
NCT02128282 2021-10-22
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Senhwa Biosciences, Inc.
Phase 1/2 Completed
NCT01949870 2016-05-13
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
AstraZeneca
Phase 1 Terminated
NCT00380588 2009-11-20
Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer
Eli Lilly and Company
Phase 2 Completed